BioTek Approves Record Capital Expenditure Budget
March 9, 2012
In support of our philosophy to manufacture and develop products exclusively in Vermont, USA, BioTek is committing a record amount for new 2012 capital investments. Highlights include:
- New computer numerically controlled (CNC) machines in manufacturing and enhanced tooling and test equipment for product assembly
- A new teleconference system supporting communication between BioTek’s Vermont headquarters and our international sales and service offices in Singapore, China, South Korea, Germany, Switzerland, France and the United Kingdom
- Additional laboratory instrumentation to support BioTek's growing application research in molecular diagnostics and cellular biology
"We are one of the few remaining microplate instrumentation suppliers that manufactures 100% of their products in the US,” notes Briar Alpert, BioTek’s President and CEO. "The capital investments that we are making this year will further enhance the quality and responsiveness of our manufacturing team, while improving the cost competiveness of the Company’s products."
Addressing BioTek’s new teleconference system, Mr. Alpert continues, "Teleconferencing at all BioTek locations will allow us to better communicate and coordinate through the entire global organization, and most importantly will provide better and faster customer feedback to our Vermont headquarters."
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. In 2011, BioTek received the North American New Product Innovation Award for Workflow Solutions in Life Sciences from Frost & Sullivan. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
For additional information, contact:
Chere Griffin, Account Executive
Shaw & Todd Advertising and Marketing Communications